Unicycive Therapeutics, Inc. (UNCY) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
UNCY Revenue Analysis (2018–2024)
As of March 2, 2026, Unicycive Therapeutics, Inc. (UNCY) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, UNCY's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $951,000 in 2022.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY). Compare UNCY vs UTHR →
Peer Comparison
Compare UNCY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UNCYCurrent | $0 | - | - | - | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-32,117,000 | - |
| 2023 | $675K | -29.0% | $675K | 100.0% | $-20,774,000 | -3077.6% |
| 2022 | $951K | - | $951K | 100.0% | $-18,052,000 | -1898.2% |
| 2021 | $0 | - | $0 | - | $-8,977,000 | - |
| 2020 | $0 | - | $0 | - | $-2,020,000 | - |
| 2019 | $0 | - | $0 | - | $-1,963,000 | - |
| 2018 | $0 | - | $0 | - | $-952,000 | - |
See UNCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UNCY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare UNCY vs AGIO
See how UNCY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is UNCY's revenue growth accelerating or slowing?
UNCY TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is UNCY's long-term revenue growth rate?
Unicycive Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is UNCY's revenue distributed by segment?
UNCY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.